Lipoprotein News and Research

RSS

A lipoprotein is a biochemical assembly that contains both proteins and lipids. The lipids or their derivatives may be covalently or non-covalently bound to the proteins.

SpectraCell Laboratories agrees to become Aetna's contracted in-network provider

SpectraCell Laboratories announced today that it has agreed with Aetna Health, one of the nation's largest health insurers, to become a contracted in-network provider. The contract provides coverage by Aetna of SpectraCell's micronutrient testing, as well as other advanced tests offered by the company.

7 Jan 2010

Advances in development of “lipidoid” formulations for systemic delivery of RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators from the David H. Koch Institute for Integrative Research at the Massachusetts Institute of Technology (MIT) today announced the publication of new data in the journal Proceedings of the National Academy of Sciences (PNAS) describing further advancements in discovery and development of novel “lipidoid” formulations for the systemic delivery of RNAi therapeutics.

30 Dec 2009

Eli Lilly and Kowa Pharmaceuticals America to co-promote LIVALO in the U.S

Eli Lilly and Company (NYSE: LLY), Kowa Company, Limited, and Kowa's U.S. subsidiary, Kowa Pharmaceuticals America, Inc., today announced that Lilly and Kowa Pharmaceuticals America have entered into a co-promotion agreement in the United States to commercialize LIVALO® (pitavastatin). Lilly and Kowa have also entered into a licensing agreement in Latin America. LIVALO is a statin approved by the U.S. Food and Drug Administration (FDA) in August 2009 for the treatment of primary hyperlipidemia and mixed dyslipidemia.

24 Dec 2009

Niacin may not be beneficial for type 2 diabetic patients

High-density lipoprotein (HDL), known as "good" cholesterol, isn't as protective for people with type 2 diabetes, according to research reported in Circulation: Journal of the American Heart Association.

22 Dec 2009

Pistachios can decrease inflammation and cardiovascular disease

New research published online, December 10, 2009 indicates that bioactive compounds in pistachios, and molecules present in pistachios, have anti-inflammatory properties.

17 Dec 2009

Low plasma CETP activity associated with increased risk of heart disease, says study

Although seen as a potential heart disease therapy, raising high-density lipoprotein (HDL) cholesterol levels by inhibiting activity of a transfer protein may not be effective, a new study suggests.

16 Dec 2009

Myrrh resin may have cholesterol-lowering properties

Laboratory experiments suggest that the resin of certain trees of the Middle East, known commonly as the "myrrh" of the Christmas story, may have cholesterol-lowering properties.

14 Dec 2009

Special issue focuses on cardiovascular disease prevention and outcomes

Emerging research on cardiovascular risk factors and treatment effects are helping clinicians gain a better understanding of which patients are most likely to benefit from close monitoring, lifestyle changes and/or additional therapeutic interventions.

14 Dec 2009

Whole genome analysis identifies 43 genetic loci contributing to lipoprotein metabolism

Using highly precise measurements of plasma lipoprotein concentrations determined by nuclear magnetic resonance spectroscopy (NMR), researchers led by Daniel Chasman at Brigham and Women's Hospital and Harvard Medical School in Boston, MA, the Framingham Heart Study in Framingham, and the PROCARDIS consortium in Stockholm, Sweden and Oxford, England performed genetic association analysis across the whole genome among 17,296 women of European ancestry from the Women's Genome Health Study.

21 Nov 2009

High blood pressure: A major risk factor for stroke and heart disease

Today, Jamieson Laboratories, in partnership with the Victorian Order of Nurses (VON), is holding a one day Blood Pressure Blitz in Toronto's underground PATH system in an effort to educate consumers about the number one risk factor for stroke and a major risk factor of heart disease.

20 Nov 2009

Findings of Merck's anacetrapib phase IIb study presented at the AHA sessions

In a phase IIb study in 589 patients with primary hypercholesterolemia or mixed hyperlipidemia treated with anacetrapib as monotherapy or co-administered with atorvastatin, there were persistent lipid effects in the higher dose arms in both the monotherapy and co-administration treatment groups eight weeks after stopping active therapy with anacetrapib.

18 Nov 2009

CRESTOR reduces major cardiovascular events in women by 46%

A new analysis of the JUPITER trial, released today at the American Heart Association meeting in Orlando, Florida, demonstrates that CRESTOR (rosuvastatin calcium) 20mg reduced first major cardiovascular events by 46%.

18 Nov 2009

Data demonstrate that danger of low levels of HDL is not reduced by statin treatment

Data released today at the American Heart Association (AHA) Scientific Sessions 2009 define the increased risk of heart attacks and cardiovascular disease in patients with low levels of HDL-C (known as "good cholesterol"). The data also determine that statins are unable to significantly impact the heart attack or cardiovascular disease risks associated with low HDL-C.

18 Nov 2009

Amsterdam Molecular Therapeutics provides third-quarter 2009 business updates

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today provides its non-audited business update in compliance with the EU transparency directive. This report summarizes material events and AMT's financial position for the third quarter of 2009.

18 Nov 2009

Genzyme and Isis Pharmaceuticals announce phase 3 study data of mipomersen

Genzyme Corp. and Isis Pharmaceuticals Inc. announced that data from the phase 3 study of mipomersen in patients with homozygous familial hypercholesterolemia (hoFH) were presented today at the American Heart Association’s Scientific Sessions.

17 Nov 2009

Aterovax presents results of its sPLA2 activity test in the PEACE trial

Aterovax SA, a company developing innovative products for atherosclerosis, today announced data demonstrating that its blood test for secretory phospholipase A2 (sPLA2) activity significantly improves cardiovascular risk prediction in patients with stable coronary artery disease (CAD) over a 5 year period, independent of established risk markers, including C-reactive protein.

17 Nov 2009

Upsher-Smith Laboratories publishes results of SLIM Study

Results of the SLIM Study ("Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia") were recently published in the Journal of Clinical Lipidology.

17 Nov 2009

Additional data from Aegerion Pharmaceuticals' ongoing lomitapide Phase III trial

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cardiovascular and metabolic disease, today announced additional data from its ongoing Phase III trial involving its lead cholesterol management compound, lomitapide (AEGR-733), which is a microsomal triglyceride transfer protein (MTP) inhibitor small molecule drug.

16 Nov 2009

Effect of niacin or ezetimibe added to chronic statin therapy on carotid intima media thickness: Study

In combination with statins, adding a medication that raises high-density lipoprotein (HDL) cholesterol was more effective in reversing artery wall plaque buildup and in reducing heart disease risk than adding a drug that lowers low-density lipoprotein (LDL) cholesterol, researchers reported today at the American Heart Association Scientific Sessions 2009.

16 Nov 2009

Results from first-in-man study of NO-donating HMG-CoA Reductase Inhibitor released

NicOx S.A. today announced that a phase 1b, first-in-man study for NCX 6560, versus placebo and Lipitor® (atorvastatin), has met its primary and secondary objectives. The top-line results demonstrated very good safety and tolerability for all the tested doses of NCX 6560, as well as the expected cholesterol lowering profile.

13 Nov 2009

Lipoprotein News and Research

Further Reading

SpectraCell Laboratories agrees to become Aetna's contracted in-network provider

Advances in development of “lipidoid” formulations for systemic delivery of RNAi therapeutics

Eli Lilly and Kowa Pharmaceuticals America to co-promote LIVALO in the U.S

Niacin may not be beneficial for type 2 diabetic patients

Pistachios can decrease inflammation and cardiovascular disease

Low plasma CETP activity associated with increased risk of heart disease, says study

Myrrh resin may have cholesterol-lowering properties

Special issue focuses on cardiovascular disease prevention and outcomes

Whole genome analysis identifies 43 genetic loci contributing to lipoprotein metabolism

High blood pressure: A major risk factor for stroke and heart disease

Findings of Merck's anacetrapib phase IIb study presented at the AHA sessions

CRESTOR reduces major cardiovascular events in women by 46%

Data demonstrate that danger of low levels of HDL is not reduced by statin treatment

Amsterdam Molecular Therapeutics provides third-quarter 2009 business updates

Genzyme and Isis Pharmaceuticals announce phase 3 study data of mipomersen

Aterovax presents results of its sPLA2 activity test in the PEACE trial

Upsher-Smith Laboratories publishes results of SLIM Study

Additional data from Aegerion Pharmaceuticals' ongoing lomitapide Phase III trial

Effect of niacin or ezetimibe added to chronic statin therapy on carotid intima media thickness: Study

Results from first-in-man study of NO-donating HMG-CoA Reductase Inhibitor released

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics